Posted by Michael Wonder on 13 Dec 2025
Quebec becomes first province in Canada to list new subcutaneous Opdivo on public drug plan for solid tumour indications
11 December 2025 - The subcutaneous administration of the established immunotherapy could free up an estimated 30,000 hours of infusion chair time, and 64,000 hours of health care professional time across Canada over three years.
Bristol Myers Squibb Canada is pleased to announce that Opdivo SC (nivolumab for subcutaneous injection) is now included on the Liste des Médicaments-Établissements.
Quebec is the first province to reimburse the new subcutaneous mode of administration for its currently authorised solid tumour indications, which previously were only funded for intravenous administration.
